Atidarsagene autotemcel
| Clinical data | |
|---|---|
| Trade names | Libmeldy |
| Other names | OTL-200 |
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| UNII | |
Atidarsagene autotemcel, sold under the brand name Libmeldy, is a gene therapy treatment for metachromatic leukodystrophy (MLD) developed by Orchard Therapeutics. It contains an autologous CD34⁺ cell enriched population that contains haematopoietic stem and progenitor cells transduced using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.[4]
Atidarsagene autotemcel was approved for medical use in the European Union in December 2020,[2][5][6] and in the United Kingdom in February 2021.[1]
Medical uses
Atidarsagene autotemcel is indicated for the treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arysulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity in children with late infantile or early juvenile forms, without clinical manifestations of the disease; and in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.[1][2][7]
Society and culture
Legal status
Atidarsagene autotemcel was approved for medical use in the European Union in December 2020.[4][2] It was approved for medical use in the UK in February 2021.[1]
Economics
In February 2022, it was announced that NHS England would be providing the drug to metachromatic leukodystrophy patients, after negotiating a discount with the manufacturer.[8][9] The assessment by BeneluxA concluded that it should only be reimbursed if the company offered a significant price reduction.[10] The National Centre for Pharmacoeconomics (NCPE) in Ireland recommends "that atidarsagene autotemcel not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatment."[7]
References
- ^ a b c d "Libmeldy - Summary of Product Characteristics (SmPC)". (emc). 28 September 2022. Retrieved 21 November 2022.
- ^ a b c d "Libmeldy EPAR". European Medicines Agency (EMA). Retrieved 3 October 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Libmeldy Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ a b "Libmeldy : EPAR - Product information". European Medicines Agency. 23 April 2021. Retrieved 3 October 2021.
- ^ "Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)". 21 December 2020.
- ^ https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-receives-ec-approval-libmeldytm-treatment/
- ^ a b "Atidarsagene autotemcel (Libmeldy). HTA ID: 21009". National Centre for Pharmacoeconomics. 30 September 2022. Retrieved 21 November 2022.
- ^ Reed, Jim (4 February 2022). "Libmeldy: World's 'most expensive' drug recommended for NHS use". BBC News Online. Retrieved 21 November 2022.
- ^ Campbell D (4 February 2022). "Children in England with fatal condition to get world's most expensive drug". The Guardian. Retrieved 4 February 2022.
- ^ "Europe: Cross-Country HTA of Gene Therapy Libmeldy Calls For Price Cut". Pink Sheet. 14 October 2022. Retrieved 9 November 2022.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |